


THE SYSTEM OF MEDICINE DEVELOPMENT



CURRENT SITUATION



PROBLEMS

No control or transparency on R&D costs and prices



Pharmaceutical companies obtain monopolies



No guarantee on Public Return on Public Investments (PRPI)



No transparency and lack of cooperation between countries during negotiations



WHAT THE EU AND THE NETHERLANDS CAN DO ABOUT IT




ADOPT LAWS TO ENSURE TRANSPARENCY ON R&D COSTS AND PRICES

ENSURE HEALTHY COMPETITION AND STOP ANTI-COMPETITIVE BEHAVIOUR

ATTACH CONDITIONS TO LICENSES ON MEDICINES DEVELOPED WITH PUBLIC MONEY

CREATE BETTER AND TRANSPARENT COOPERATION IN NEGOTIATIONS

FAIR SITUATION



RESULT

- High costs lead to no access or unequal access to medicines or
- Access through insurance, but at high societal cost



RESULT

Equal access to fairly priced medicines, reimbursed by insurance

